Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Subcutaneous vs Intravenous Aducanumab in Healthy Participants
NCT02782975Phase 1Completed
- Sponsor
- Biogen
- Start
- May 2016
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aducanumab in Alzheimer's disease (AD) (2 arms), sponsored by Biogen. Primary endpoints: Absolute Bioavailability of SC dose of aducanumab at 13 weeks, Area under the concentration-time curve from time zero to infinity at 13 weeks and 2 more. Started May 2016; status: completed.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02782975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02782975.